10.22376/ijpbs.2019.10.1.p1-12 Volume 6 Issue 4 2015 (October - December) The present work deals with isolation, identification of bioactive metabolite produced by lessThan i greaterThan Streptomyces toxytricini lessThan /i greaterThan JAR4 for various biological activities. The bioactive metabolite (1s,5s)-9-(2,6,6-trimethylbicyclo[3.1.1]heptan-3-yl)-9-borabicyclo[3.3.1]nonane produced by the strain JAR4 was obtained from the optimized culture medium through solvent extraction and molecular weight of the metabolite was characterized through Gas-chromatography mass spectrometry. The active constituents obtained after extraction and partial purification from the isolate JAR4 was tested against clinical pathogens and it was found to be efficiently inhibiting lessThan i greaterThan Pseudomonas aeruginosa, Salmonella sp., Staphylococcus aureus lessThan /i greaterThan and lessThan i greaterThan Klebsiella pnuemoniae lessThan /i greaterThan among various gram positive and gram negative pathogens. The lessThan i greaterThan in silico lessThan /i greaterThan studies of the isolated bioactive compound reveal the binding with glutamine 6-phosphate synthase at active binding site when compared with standard antibiotic anticapsin through molecular docking performed by Autodock vina. Actinomycetes are the prolific source of antimicrobial metabolites therefore the present investigation reveals in vitro as well as lessThan i greaterThan in silico lessThan /i greaterThan antimicrobial potential of terrestrial actinomycetes JAR4 against medically important clinical pathogens. JAYANTHI ABRAHAM AND RITIKA CHAUHAN Antibiotics; Actinomycetes; Pathogens; Streptomyces toxytricini JAR4; GC-MS 265-276